8.30: Specialty Pharmaceuticals: Market Overview

This session will discuss the current and future role of specialty pharmaceuticals in the U.S. health system. What are specialty pharmaceuticals and what makes them different from other drugs? What are recent and projected trends in their use and cost? What percentage of the population depends on them? What are the economics of specialty drugs for physicians, hospitals, and academic medical centers? How are specialty drugs covered and financed by Medicare and private insurers? What are future challenges for ensuring that specialty pharmaceuticals are used appropriately?

Presenter: Debbie Stern, Vice President, Rxperts Inc.

9.30: Specialty Pharmaceutical Management Strategies

Commercial Market
- Presentation 1: Margaret M. Johnson, R.Ph., Vice President, Chief Pharmacy Officer, Horizon BCBS of New Jersey
- Respondent: Scott Howell, MD, Senior Director of Contracting Strategy, Genentech

Medicare and Medicaid
- Presentation 2: Dan Mendelson, President, Avalere Health
- Respondent: Matt Eyles, Vice President for Public Policy, Wyeth

11.00: Break

11.30: Social Policy Issues for Controlling Specialty Pharmaceutical Spending

This session will discuss social policy facing health plans, purchasers, and public officials as they try to balance access and affordability for specialty pharmaceuticals.

Moderator: Stuart Altman, Ph.D., The Heller School, Brandeis University

Panelists: Kathy Buto, Vice President for Policy, Johnson & Johnson
Edmund Pezalla, MD, National Medical Director and Chief Clinical Officer, Aetna Pharmacy Management
Joseph Jacobson, MD, Chairman of Medicine, North Shore Medical Center
Bari Talente, Associate Vice President, State and Local Government Relations, National Multiple Sclerosis Society

12.45: Lunch

Speaker: Uwe Reinhardt Ph.D, Professor, Princeton University